Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 4
1951 1
1952 1
1954 1
1955 3
1956 1
1957 1
1958 1
1959 1
1960 1
1961 2
1962 3
1963 1
1964 3
1965 2
1966 3
1967 6
1968 6
1969 3
1970 1
1971 5
1972 6
1973 3
1974 3
1975 4
1976 7
1977 8
1978 3
1979 4
1980 4
1981 3
1982 6
1983 9
1984 6
1985 6
1986 7
1987 8
1988 14
1989 31
1990 20
1991 17
1992 14
1993 16
1994 12
1995 23
1996 20
1997 29
1998 20
1999 17
2000 18
2001 19
2002 14
2003 12
2004 17
2005 20
2006 37
2007 30
2008 20
2009 27
2010 29
2011 32
2012 30
2013 48
2014 43
2015 64
2016 69
2017 65
2018 58
2019 61
2020 59
2021 64
2022 58
2023 57
2024 64
2025 72

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,327 results

Results by year

Filters applied: . Clear all
Page 1
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy.
Santich BH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach DR, Fung EK, Patel M, Burnes Vargas D, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, Larson SM, Cheung NK. Santich BH, et al. Among authors: michel ao. Clin Cancer Res. 2021 Jan 15;27(2):532-541. doi: 10.1158/1078-0432.CCR-20-2150. Epub 2020 Sep 21. Clin Cancer Res. 2021. PMID: 32958698 Free PMC article.
212Pb-Pretargeted Theranostics for Pancreatic Cancer.
Bauer D, Carter LM, Atmane MI, De Gregorio R, Michel A, Kaminsky S, Monette S, Li M, Schultz MK, Lewis JS. Bauer D, et al. Among authors: michel a. J Nucl Med. 2024 Jan 2;65(1):109-116. doi: 10.2967/jnumed.123.266388. J Nucl Med. 2024. PMID: 37945380 Free PMC article.
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen JN, Abrams TA, Clark JW, Enzinger AC, Enzinger PC, Klempner SJ, McCleary NJ, Meyerhardt JA, Ryan DP, Yurgelun MB, Kanter K, Van Seventer EE, Baiev I, Chi G, Jarnagin J, Bradford WB, Wong E, Michel AG, Fetter IJ, Siravegna G, Gemma AJ, Sharpe A, Demehri S, Leary R, Campbell CD, Yilmaz O, Getz GA, Parikh AR, Hacohen N, Corcoran RB. Tian J, et al. Among authors: michel ag. Nat Med. 2023 Feb;29(2):458-466. doi: 10.1038/s41591-022-02181-8. Epub 2023 Jan 26. Nat Med. 2023. PMID: 36702949 Free PMC article. Clinical Trial.
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, Pétremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroyannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, Stevenson BJ, Iseli C, Levine BL, Speiser DE, Gfeller D, Bassani-Sternberg M, Powell DJ Jr, June CH, Dafni U, Kandalaft LE, Harari A, Coukos G. Bobisse S, et al. Among authors: michel a. Nat Cancer. 2023 Oct;4(10):1410-1417. doi: 10.1038/s43018-023-00623-x. Epub 2023 Sep 21. Nat Cancer. 2023. PMID: 37735588 Clinical Trial.
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.
Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB. Tanaka N, et al. Among authors: michel ag. Cancer Discov. 2021 Aug;11(8):1913-1922. doi: 10.1158/2159-8290.CD-21-0365. Epub 2021 Apr 6. Cancer Discov. 2021. PMID: 33824136 Free PMC article.
Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution.
Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, Scheiwe C, Nessler S, Kunz P, van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, Gold R, Grün D, Priller J, Stadelmann C, Prinz M. Masuda T, et al. Among authors: michel a. Nature. 2019 Feb;566(7744):388-392. doi: 10.1038/s41586-019-0924-x. Epub 2019 Feb 13. Nature. 2019. PMID: 30760929
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
Chiffelle J, Barras D, Pétremand R, Orcurto A, Bobisse S, Arnaud M, Auger A, Rodrigo BN, Ghisoni E, Sauvage C, Saugy D, Michel A, Murgues B, Fahr N, Imbimbo M, Ochoa de Olza M, Latifyan S, Crespo I, Benedetti F, Genolet R, Queiroz L, Schmidt J, Homicsko K, Zimmermann S, Michielin O, Bassani-Sternberg M, Kandalaft LE, Dafni U, Corria-Osorio J, Trueb L, Dangaj Laniti D, Harari A, Coukos G. Chiffelle J, et al. Among authors: michel a. Immunity. 2024 Oct 8;57(10):2466-2482.e12. doi: 10.1016/j.immuni.2024.08.014. Epub 2024 Sep 13. Immunity. 2024. PMID: 39276771 Free article.
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Taniguchi H, Caeser R, Chavan SS, Zhan YA, Chow A, Manoj P, Uddin F, Kitai H, Qu R, Hayatt O, Shah NS, Quintanal Villalonga Á, Allaj V, Nguyen EM, Chan J, Michel AO, Mukae H, de Stanchina E, Rudin CM, Sen T. Taniguchi H, et al. Among authors: michel ao. Cell Rep. 2022 May 17;39(7):110814. doi: 10.1016/j.celrep.2022.110814. Cell Rep. 2022. PMID: 35584676 Free PMC article.
1,327 results